Publication Cover
Archives of Andrology
Journal of Reproductive Systems
Volume 18, 1987 - Issue 3
34
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Protection of Spermatogenesis During Cancer Chemotherapy

Pages 211-213 | Received 20 Oct 1986, Accepted 06 Nov 1986, Published online: 09 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

O. K. Schlappack, J. I. Delic, J. R. Harwood & J. A. Stanley. (1987) Attempted Protection of Spermatogenesis From Single Doses of Gamma-Irradiation in the Androgen Pretreated Rat. Archives of Andrology 19:3, pages 269-274.
Read now

Articles from other publishers (5)

Ebenezer Tunde Olayinka, Ayokanmi Ore, Oluwatobi Adewumi Adeyemo & Olaniyi Solomon Ola. (2019) The role of flavonoid antioxidant, morin in improving procarbazine-induced oxidative stress on testicular function in rat. Porto Biomedical Journal 4:1, pages e28.
Crossref
J. F. Velez De La Calle, M. Ben Hassel & B. Jegou. (1995) Protection gonadique contre les effets iatrogènes des traitements anticancéreux: données expérimentalesProtection of the testis against side effects of cancer therapy: experimentation in animal. Andrologie 5:4, pages 498-503.
Crossref
N. PARCHURI, G. WILSON & M. L. MEISTRICH. (2013) Protection by Gonadal Steroid Hormones Against Procarbazine‐Induced Damage to Spermatogenic Function in LBNF 1 Hybrid Rats . Journal of Andrology 14:4, pages 257-266.
Crossref
I. D. MORRIS, C. W. BARDIN, G. GUNSALUS & J. A. WARD. (2008) Prolonged suppression of spermatogenesis by oestrogen does not preserve the seminiferous epithelium in procarbazine‐treated rats. International Journal of Andrology 13:3, pages 180-189.
Crossref
W. Krause & K.H. Pflüger. (2009) Treatment with the Gonadotropin-Releasinghormone Agonist Buserelin to Protect Spermatogenesis against Cytotoxic Treatment in Young Men/Behandlung zum Schutz der Spermatogenese bei cytotoxischer Therapie mit dem Gonadotropin-Hormon Agonisten Buserelin. Andrologia 21:3, pages 265-270.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.